Drug Catalog - Product Detail
HYDROCORTISONE ACET (PROCTOZONE-HC CRM) CRM 0.025 1OZ
| NDC | Mfr | Size | Str | Form |
|---|---|---|---|---|
| 64980-0324-30 | RISING PHARMACEUTICALS | 30 | 2.5% | CREAM |
PACKAGE FILES
Generic Name
HYDROCORTISONE 2.5%
Substance Name
HYDROCORTISONE
Product Type
HUMAN PRESCRIPTION DRUG
Route
TOPICAL
Application Number
ANDA040879
Description
DESCRIPTION Each gram of Proctozone-HC ® (Hydrocortisone Cream, USP 2.5%) contains 25 mg of hydrocortisone in a water-washable base of purified water, propylene glycol, glyceryl monostearate SE, cholesterol, isopropyl myristate, polysorbate 60, cetyl alcohol, sorbitan monostearate, polyoxyl 40 stearate, sorbic acid, methylparaben, and propylparaben. Chemically, hydrocortisone is [Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11β)-] with the molecular formula (C 21 H 30 O 5 ) and is represented by the following structural formula: Its molecular weight is 362.46 and its CAS Registry Number is 50-23-7. The topical corticosteroids, including hydrocortisone, constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. structure
How Supplied
HOW SUPPLIED PROCTOZONE-HC ® 2.5% (Hydrocortisone Cream, USP 2.5%) Tubes containing 30 g (1.1 oz) NDC 64980-324-30 Storage Keep tightly closed. Store at 20° – 25° C (68° – 77° F) excursion permitted to 15° – 30° C (59° – 86° F) [See USP Controlled Room Temperature]. Keep out of the reach of children. Distributed by: Manufactured by: Rising Pharmaceuticals, Inc. Lyne Laboratories, Inc. East Brunswick, NJ 08816 Brockton, MA 02301 R4-02/23 PIR32430-01
Indications & Usage
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
DOSAGE AND ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.